To investigate the variations in the humoral response to vaccines for the prevention of COVID-19 in liver transplant patients based on the type of immunosuppressive therapy adopted (tacrolimus based vs no-tacrolimus based) and immunosuppressive blood levels.
Study Type
OBSERVATIONAL
Enrollment
61
Blood test to value the antibody response to vaccination
Policlinico Tor Vergata
Roma, Italy
Rate of positive antibody titer
\> 0.8 U/mL
Time frame: Between 30 and 120 ± 15 days after the completion of the vaccination cycle
Rate of highly protective antibody titer
\>100 BAU/mL
Time frame: Between 30 and 120 ± 15 days after the completion of the vaccination cycle
Median antibody titer absolute value
BAU/mL
Time frame: Between 30 and 120 ± 15 days after the completion of the vaccination cycle
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.